Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin + lascufloxacin 7-day rescue therapy for Helicobacter pylori
jRCTs031200154Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, amoxicillin and lascufloxacin in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate (FAS). Started Nov 2020; status: active, not recruiting.
02
Drugs
vonoprazanamoxicillinlascufloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031200154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200154.